News
VERU
1.390
-2.11%
-0.030
Weekly Report: what happened at VERU last week (0513-0517)?
Weekly Report · 1d ago
BRIEF-Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
Veru Announces Steven B. Heymsfield as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss. The company is developing a drug to help people lose weight and improve their quality of life. Veru says the trial will be conducted in the United States.
Reuters · 6d ago
Veru Initiated at Buy by B. Riley Securities
Dow Jones · 05/14 09:58
Veru Price Target Announced at $5.00/Share by B. Riley Securities
Dow Jones · 05/14 09:58
B. Riley Securities Initiates Coverage On Veru with Buy Rating, Announces Price Target of $5
Benzinga · 05/14 09:48
Buy Rating for Veru Inc. on Promising Enobosarm Trials and Strategic Market Positioning
William Wood, an analyst from Financial, has initiated a new Buy rating on Veru (VERU) Veru's product, enobosarm, is designed to improve muscle and bone strength in patients using GLP1-based drugs. The company is focusing on the weight loss market.
TipRanks · 05/14 00:16
Weekly Report: what happened at VERU last week (0506-0510)?
Weekly Report · 05/13 11:33
Buy Rating Affirmed on Veru Amid Strong Clinical Prospects and Solid Financial Position
TipRanks · 05/10 14:15
Veru Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/09 04:08
VERU Stock Earnings: Veru Misses EPS, Beats Revenue for Q2 2024
Veru reported results for the second quarter of 2024. Veru reported earnings per share of -7 cents. The company reported revenue of $4.14 million. This was 37.83% better than the analyst estimate for revenue of -5 cents.
Investorplace · 05/08 14:54
Veru Inc reports results for the quarter ended in March - Earnings Summary
Veru Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 7 cents per share. Revenue fell 37.2% to $4.14 million from a year ago. Veru Inc shares had risen by 132.8% this quarter.
Reuters · 05/08 13:52
Veru Q2 2024 Adj EPS $(0.07) Misses $(0.05) Estimate, Sales $4.10M Beat $3.00M Estimate
Veru reported quarterly losses of $0.07 per share and sales of $4.10 million. The company missed the analyst consensus estimate of $3.00 million by 40 percent. Veru also reported a 37.75 percent decrease in sales from the same period last year.
Benzinga · 05/08 10:33
BRIEF-Veru Q2 Revenue USD 4.1 Million
Reuters · 05/08 10:30
VERU REPORTS FISCAL 2024 SECOND QUARTER FINANCIAL RESULTS AND PROGRESS OF ITS ENOBOSARM HIGH QUALITY WEIGHT LOSS CLINICAL PROGRAM
Reuters · 05/08 10:30
VERU INC: PHASE 2B CLINICAL STUDY OF ENOBOSARM IN COMBINATION WITH SEMAGLUTIDE (WEGOVY ) FOR HIGH QUALITY WEIGHT LOSS IS ACTIVELY ENROLLING
Reuters · 05/08 10:30
*Veru 2Q Rev $4.14M >VERU
Dow Jones · 05/08 10:30
Veru Q2 2024 Earnings Preview
Seeking Alpha · 05/07 16:06
Veru Inc <VERU.OQ> expected to post a loss of 5 cents a share - Earnings Preview
Veru Inc expected to report a 54.4% fall in quarterly revenue to $3 million from $6.59 million. The company is expected to post a loss of 5 cents a share. The average analyst estimate for Veru Inc's quarterly revenue is for a fall of 54.5%.
Reuters · 05/06 17:20
Critical Insights From Veru Analyst Ratings: What You Need To Know
Veru Inc is a biopharmaceutical company with a drug development program. The company's revenue growth lags behind its peers. Veru has an average 12-month price target of $3.25. 4 analysts have shared their evaluations of Veru during the recent three months.
Benzinga · 05/06 13:01
Weekly Report: what happened at VERU last week (0429-0503)?
Weekly Report · 05/06 11:41
More
Webull provides a variety of real-time VERU stock news. You can receive the latest news about Veru through multiple platforms. This information may help you make smarter investment decisions.
About VERU
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.